Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.35 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.35 |
| ▸ | MELK | Q14680 | 3/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18057512 | 0.91 | JAK2 (0.38) | JAK2JAK3BTKHRH4ATR | |
| SCHEMBL18057536 | 0.88 | PARP1 (0.38) | JAK2JAK3HRH4KMT2APARP1 | |
| SCHEMBL18057491 | 0.87 | MELK (0.34) | JAK2JAK3HRH4MRGPRX2MELK | |
| SCHEMBL18057531 | 0.87 | HRH4 (0.40) | JAK2JAK3BTKHRH4ATR | |
| SCHEMBL18057528 | 0.85 | HRH4 (0.35) | HRH4MRGPRX2MELKMEN1KMT2A | |
| SCHEMBL18057547 | 0.85 | PDE4B (0.38) | HRH4MRGPRX2MELKPARP1 | |
| SCHEMBL18057497 | 0.84 | HRH4 (0.37) | JAK2JAK3BTKHRH4MEN1 | |
| SCHEMBL18057534 | 0.79 | PARP1 (0.40) | JAK2JAK3HRH4KMT2APARP1 | |
| SCHEMBL18057500 | 0.78 | MTOR (0.36) | JAK2JAK3HRH4MEN1KMT2A | |
| SCHEMBL18057517 | 0.77 | PDE4B (0.40) | JAK2JAK3HRH4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745403-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10590134-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10442801-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2019-10-15 | — | — | US | disclosed |
| US-9951066-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2018-03-22 | — | — | US | disclosed |
| US-20170334905-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2017-11-23 | — | — | US | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590134-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | JAK2 1732/4885JAK3 2671/4885BTK 2981/4885 |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | JAK2 2706/4885JAK3 3414/4885BTK 3531/4885 |
| US-10745403-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | JAK2 1732/4885JAK3 2671/4885BTK 2981/4885 |
| US-20170334905-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | JAK2 2706/4885JAK3 3414/4885BTK 3531/4885 |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | JAK2 2706/4885JAK3 3414/4885BTK 3531/4885 |
| US-10442801-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | JAK2 1732/4885JAK3 2671/4885BTK 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.